查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1736516

全球炭疽疫苗市場 - 市場規模（按產品類型、應用、最終用戶、地區、預測）

Global Anthrax Vaccines Market Size By Product Type (Cell-Free PA Vaccines, Live Cells), By Application (Animal Use, Human Use), By End-User (Hospital Pharmacy, Retail pharmacy), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 | 商品交期: 2-3個工作天內

價格
簡介目錄

炭疽疫苗市場規模及預測

2024 年炭疽疫苗市場規模為 131.7 億美元，預計到 2032 年將達到 292.7 億美元，2026 年至 2032 年的複合年成長率為 5.59%。

由於炭疽疫情的增多，全球炭疽疫苗市場正快速成長。炭疽疫苗市場的成長動力源自於未煮熟的病畜肉和生肉消費量的增加。此外，生皮和毛紡織物等受​​污染商品的工業或製造加工也促進了市場的成長。全球炭疽疫苗市場報告提供了市場的整體評估，全面分析了關鍵細分市場、趨勢、市場促進因素、限制、競爭格局以及影響市場的關鍵因素。

定義炭疽疫苗的全球市場

炭疽病是由炭疽菌引起的一種危險感染疾病。目前已有疫苗可以預防。但這種疫苗通常不會向公眾提供。它只適用於感染炭疽病風險高或已經接觸炭疽菌炭疽菌的人。炭疽病是由革蘭氏陽性細菌炭疽菌孢子引起的一種嚴重感染疾病。感染途徑主要有四種：肺部、腸道、皮膚和注射。人類和動物都容易受到炭疽菌感染，尤其是牛、羊、山羊和馬等反芻動物。炭疽菌很難在人與人之間傳播。

炭疽病的症狀和徵兆因感染類型而異。皮膚炭疽病、胃腸道炭疽病、吸入性炭疽病和注射性炭疽病的症狀各不相同。胃腸道炭疽病最常見的症狀是噁心、腹痛、食慾不振、嘔吐、發燒、血性腹瀉、頸部腫脹、頭痛和吞嚥困難。吸入性炭疽病可能導致呼吸急促、咳血、吞嚥困難、輕微胸部不適和噁心。注射性炭疽病最常見的徵兆和症狀是多重器官衰竭、腦膜炎和注射部位周圍發紅。

目前，世界各地炭疽病的診斷方法是檢體患者血液中是否有抗體或毒素。此外，醫學專家建議進行直接檢測以診斷是否感染炭疽菌。炭疽菌疫苗有無細胞疫苗和活病毒疫苗兩種形式。接種炭疽菌疫苗的主要原因是吸入感染的風險。作為暴露前疫苗，使用無細胞疫苗（炭疽疫苗吸附劑，AVA），該疫苗含有炭疽毒素成分，接種 3 至 6 劑後可提供保護性免疫。沉澱炭疽疫苗（AVP）初次接種三次，6 個月後加強接種。每 12 個月需要接種一次加強劑以誘導和維持保護性免疫。

目前的炭疽疫苗在局部和全球範圍內都具有高度反應性（紅斑、硬結、疼痛、發熱）。約1%的疫苗接種有嚴重的副作用。重組活病毒疫苗次單位疫苗疫苗是目前正在研發的兩種新型第二代疫苗。炭疽疫苗吸附劑（AVA）或BioThraxTM是唯一獲得許可的炭疽疫苗，建議用於18至65歲炭疽菌高危險群的主動免疫接種，以預防炭疽菌。位於密西根州蘭辛的Emergent BioDefense Operations Lansing Inc.自1970年以來已獲得生產該疫苗的許可。目前有多家公司正在研發下一代炭疽疫苗。

全球炭疽疫苗市場概況

由於炭疽菌發病率不斷上升，炭疽疫苗市場蓬勃發展。全球市場的主要驅動力是食用生的和未煮熟的感染動物肉的現像日益流行。此外，毛紡織物和皮革等受污染動物產品的商業性和工業加工大幅增加也推動了市場的成長。炭疽菌最常見於野生動物和家畜。隨著世界各地畜牧業的興起，農場的數量也增加。在農場工作使人們與動物近距離接觸，使他們面臨感染炭疽菌的風險。這個因素是市場的主要驅動力。

同時，炭疽病自願篩檢率低可能是炭疽疫苗市場發展的一大障礙。此外，非洲等地區對炭疽菌診斷檢測缺乏了解，導致企業難以直接接觸客戶，阻礙了市場成長。炭疽菌患病率上升以及未煮熟和生肉消費量增加等因素是市場成長的主要驅動力。透過改善診斷、監測和疫情應對措施，可以預防動物和人類感染炭疽病。此疾病的高發生率、感染風險和嚴重程度使其成為預防保健機構的首要任務之一。

炭疽菌是透過食用受感染的肉類在動物體內傳播的。儘管雞肉、牛肉和豬肉的消費模式差異很大，但所有這些消費模式都會增加炭疽病的風險。鑑於上述情況，炭疽疫苗市場在預測期內可能會擴大。該市場由少數參與者主導，預計在預測期內可能會有所發展，然而，缺乏對診斷和篩檢檢測的認知以及炭疽疫苗價格過高等因素可能會阻礙市場擴張。

目錄

第1章全球炭疽疫苗市場簡介

  • 市場概覽
  • 研究範圍
  • 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

第4章炭疽疫苗全球市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

5. 全球炭疽疫苗市場（依產品類型）

  • 概述
  • 無細胞PA疫苗
    • AVA
    • AVP
  • 活細胞

6. 全球炭疽疫苗市場（依應用）

  • 概述
  • 對人類來說
  • 對於動物

7. 全球炭疽疫苗市場（依最終用戶）

  • 概述
  • 醫院藥房
  • 零售藥局
  • 其他

8. 全球炭疽疫苗市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 世界其他地區
    • 拉丁美洲
    • 中東和非洲

9. 全球炭疽疫苗市場競爭格局

  • 概述
  • 各公司市場排名
  • 主要發展策略

第10章 公司簡介

  • Zoetis Inc.
  • Emergent Bio-Solutions
  • Merck & Co. Inc.
  • Colorado Serum
  • PharmaAthene Inc.
  • Vecol
  • Biogenesis Bago Inc.
  • Porton Biopharma Inc.
  • Merial
  • Intervac

第11章 重大進展

  • 產品發布/開發
  • 合併與收購
  • 業務擴展
  • 夥伴關係與合作

第12章 附錄

  • 相關調查
簡介目錄
Product Code: 37346

Anthrax Vaccines Market Size And Forecast

Anthrax Vaccines Market size was valued at USD 13.17 Billion in 2024 and is projected to reach USD 29.27 Billion by 2032, growing at a CAGR of 5.59 % during the forecast period 2026-2032.

Because of the rising prevalence of the disease, the global market for anthrax vaccinations is rapidly growing. The market for anthrax vaccinations is driven by the increased consumption of undercooked or raw meat from diseased animals. Increased industrial or manufacturing processing of contaminated commodities like skins and hair wool will also help to grow the market. The Global Anthrax Vaccines Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Anthrax Vaccines Market Definition

Anthrax is a dangerous infection caused by the bacteria Bacillus anthracis. There is a vaccination that can help avoid it. This vaccination, however, is not normally available to the general population. It is only indicated for persons who are at a high risk of contracting B. anthracis or who have already been exposed to it. Anthrax is a serious infectious disease caused by the spores of Bacillus anthracis, a gram-positive bacterium. The lungs, intestines, skin, and injectables are the four main routes of infection. Both humans and animals are susceptible to anthrax, particularly ruminants like cattle, sheep, goats, and horses. It is difficult to spread from one individual to another.

Anthrax symptoms and signs differ based on the type of infection. The symptoms of cutaneous anthrax, gastrointestinal anthrax, inhalation anthrax, and injectable anthrax differ. The most common signs and symptoms of gastrointestinal anthrax include nausea, abdominal pain, lack of appetite, vomiting, fever, bloody diarrhea, swelling neck, headache, and difficulty swallowing. Inhalation anthrax causes shortness of breath, blood in the cough, uncomfortable swallowing, minor chest discomfort, and nausea. The most common indications and symptoms of injectable anthrax are multiple organ failure, meningitis, and redness around the injection site.

Currently, the primary approaches in the diagnosis of anthrax available worldwide rely on the presence or absence of antibodies or toxins in a patient's blood sample. Furthermore, healthcare professionals advised using direct testing to diagnose the presence of Bacillus anthracis. Anthrax vaccinations are available in both cell-free and live forms. The main reason for anthrax immunization is the danger of infection through inhalation. An acellular vaccine (anthrax vaccine adsorbed or AVA), which contains anthrax toxin components and results in protective immunity after 3 to 6 doses, is used as a pre-exposure vaccine. Anthrax vaccine precipitated (AVP) is given in three doses at prime vaccination, with a booster dose 6 months later. A booster dose is required once every 12 months to elicit and sustain protective immunity.

Current anthrax vaccinations have a high level of local and overall reactogenicity (erythema, induration, soreness, fever). About 1% of immunizations have serious side effects. Recombinant live vaccines and recombinant sub-unit vaccines are the two new second-generation vaccines that are currently in development. Anthrax Vaccine Adsorbed (AVA) or BioThraxTM, the only licensed anthrax vaccine, is recommended for active vaccination for the prevention of disease caused by Bacillus anthracis in those aged 18 to 65 who are at a high risk of exposure. Emergent BioDefense Operations Lansing Inc. in Lansing, Michigan, has been licensed to manufacture the vaccine since 1970. Multiple companies are working on next-generation anthrax vaccinations.

Global Anthrax Vaccines Market Overview

Because of the rising occurrence of anthrax, the Anthrax Vaccines Market is fast growing. A major driver of the global market is the rise in popularity of eating raw and undercooked meat from infected animals. Furthermore, a large increase in the commercial and industrial processing of contaminated animal commodities such as hair wool, and hide boosted the market growth. Anthrax is most commonly seen in wild wildlife and livestock. The number of farms is growing as animal husbandry becomes more popular around the world. Working on farms puts people in close proximity to animals, putting them at risk of contracting anthrax. This element operates as the market's primary driving force.

The low percentage of voluntarily screening for anthrax disease, on the other hand, could be a major impediment to the Anthrax Vaccines Market. Furthermore, in places like Africa, a lack of understanding regarding anthrax diagnostic tests makes it difficult for companies to reach out directly to their clients, stifling market growth. Factors such as the rising prevalence of anthrax and the expanding consumption of undercooked or raw meat are mostly to blame for the market's expansion. It may be possible to avoid it in both animals and humans by improving diagnosis, surveillance, and outbreak response. The disease has a high prevalence rate, and the risk and severity of infection make it one of the top priorities for preventive healthcare organizations.

Anthrax has been found in animals as a result of infected meat. Although the consumption patterns in chicken, beef, and pork are substantially different, they all raise the risk of anthrax. As a result of the foregoing, the Anthrax Vaccines Market is likely to expand over the forecast period. Although the market is dominated by a few players and is likely to develop over the forecast period, factors such as a lack of awareness regarding diagnostic and screening tests and the anthrax vaccine's exorbitant cost may hinder market expansion.

Global Anthrax Vaccines Market Segmentation Analysis

The Global Anthrax Vaccines Market is segmented based on Product Type, Application, End-User, And Geography.

Based on the Product Type, the market is bifurcated into Cell-Free PA Vaccines and Live Cells. Cell-Free PA Vaccines are expected to hold the largest market share in the coming years.

Anthrax Vaccines Market, By Application

  • Animal Use
  • Human UseBased on Application, the market is bifurcated into Animal Use And Human Use. The animal use anthrax vaccination segment is expected to dominate the market. Anthrax is an epizootic disease that spreads from animals to humans and appears in sensitive animals, both wild and domesticated, on a regular basis. Anthrax is acute septicemia with a high fatality rate in herbivore animals such as cattle, sheep, goats, camels, and antelopes. It is generally accompanied by hemorrhagic lymphadenitis. In dogs, pigs, and horses, however, it is a less severe but possibly lethal condition.

Anthrax Vaccines Market, By End-User

  • Hospital Pharmacy
  • Retail pharmacy
  • Others

Based on End-User, the market is bifurcated into Hospital Pharmacy, Retail pharmacy, and Others. Hospital pharmacies dominated the market. Hospitals serve as a key immunization venue, which explains why anthrax vaccine sales are so high there. Anthrax vaccines are, additionally, routinely administered to patients in hospitals.

Anthrax Vaccines Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of Geography, the Global Anthrax Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The largest share in the market will be dominated by North America owing to the growing number of anthrax patients.

Key Players

The "Global Anthrax Vaccines Market" study report will provide a valuable insight with an emphasis on global market including some of the major players such as Zoetis Inc., Emergent Bio-Solutions, Merck & Co. Inc., Colorado Serum, PharmaAthene Inc., Vecol, Biogenesis Bago Inc., Porton Biopharma Inc., Merial, and Intervac.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Key Developments

  • In August 2020, Anthim (obiltoxaximab for injection), a monoclonal antibody (mAb) anthrax antitoxin, developed by Elusys Therapeutics Inc. (Elusys), obtained approval from Health Canada for the treatment of inhalation anthrax and can be used to treat post-exposure prophylaxis in both adults and children.
  • In August 2020, Dr. Jamie Benn Felix and the Cook Wildlife Lab team from Texas A&M University College of Veterinary Medicine & Biomedical Sciences performed pilot research for the first oral anthrax vaccine for livestock (CVMBS).

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ANTHRAX VACCINES MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL ANTHRAX VACCINES MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL ANTHRAX VACCINES MARKET, BY PRODUCT TYPE

  • 5.1 Overview
  • 5.2 Cell-Free PA Vaccines
    • 5.2.1 Anthrax Vaccine Adsorbed (AVA)
    • 5.2.2 Anthrax Vaccine Precipitated (AVP)
  • 5.3 Live Cells

6 GLOBAL ANTHRAX VACCINES MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Human Use
  • 6.3 Animal Use

7 GLOBAL ANTHRAX VACCINES MARKET, BY END-USER

  • 7.1 Overview
  • 7.2 Hospital Pharmacy
  • 7.3 Retail pharmacy
  • 7.4 Others

8 GLOBAL ANTHRAX VACCINES MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East & Africa

9 GLOBAL ANTHRAX VACCINES MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Zoetis Inc.
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Emergent Bio-Solutions
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Merck & Co. Inc.
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Colorado Serum
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 PharmaAthene Inc.
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Vecol
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Biogenesis Bago Inc.
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Porton Biopharma Inc.
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Merial
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Intervac
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

  • 12.1 Related Research